Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Disitamab vedotin + radiotherapy + sintilimab + capecitabine as neoadjuvant therapy for HER2-positive locally advanced gastric cancer
ChiCTR2600118406Phase 2Recruiting
- Sponsor
- Affiliated Cancer Hospital of Nanjing Medical University
- Start
- Feb 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of disitamab vedotin in gastric cancer (GC) and gastroesophageal junction adenocarcinoma, sponsored by Affiliated Cancer Hospital of Nanjing Medical University. Primary endpoint: pathological complete response rate. Started Feb 2026; status: recruiting.
02
Drugs
disitamab vedotin
03
Conditions
gastric cancer (GC)gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on ChiCTR2600118406.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600118406.